Product Catalog

HOME / BRACHYTHERAPY SOLUTIONS / PRODUCTS / SEEDS / THERASEED® – PD-103

TheraSeed® Palladium-103
Brachytherapy Seed

Setting the standard in Palladium seed technology

Backed by Theragenics’ trusted quality and expertise and supported by more than 35 years of clinical use, TheraSeed® PD-103 is globally recognized as the industry standard for Palladium seed technology.

THE POWER
OF ONE LITTLE SEED...
THE POWER
TO IMPACT A PATIENT'S LIFE

* Seed not to scale – TheraSeed is 4.5mm long x 0.8mm high

Exclusive design

  • Distinctive concave end cups designed to facilitate tissue fixity
  • Laser welded titanium capsule containing two Pd-103 plated graphite pellets and a lead x-ray marker
  • Available in a wide range of activities with both standard and high activity options

Unrivalled clinical experience

  • Pd-103 shorter half-life and lower energy photons provide distinct radiobiologic advantages over I-125, and may achieve greater disease control over I-1251
  • Pd-103 implants demonstrate greater dose heterogeneity, which is associated with improved oncologic outcomes1

Trusted quality

  • Pd-103 produced on our own cyclotrons and seeds manufactured in Buford, GA
  • Dosimetric characterization of TheraSeed® Pd-103 include Monte Carlo and experimental studies conducted in accordance with the AAPM Task Group 43 update (TG43U2)2

TheraSeed® can be supplied in a range of brachytherapy devices and delivery methods

We understand that every clinical team has unique needs and workflows. That’s why we offer a range of LDR brachytherapy solutions designed to provide flexibility, procedural efficiency, and value.

 

From loose seeds and preloaded needles to cartridges and braided sutures, Theragenics offers a comprehensive range of LDR brachytherapy solutions designed to support your procedural needs and patient care.

 

We offer a comprehensive portfolio of strands, preloaded needles, carriers, and fiducial markers, backed by personalized customer service. We remain committed to investing in innovative solutions that support targeted, minimally invasive treatment and evolving clinical needs.

Preloaded Brachytherapy Needle Trays

Preloaded Brachytherapy Needle Trays

Configurations & Carriers

ANCHORSEED Proprietary, synthetic bio-absorbable polymer seed encapsulation design

ANCHORSEED Bio-absorbable polymer seed

Configurations & Carriers

C20 Brachytherapy Seed Cartridges

C20 Brachytherapy
Seed Cartridges

Configurations & Carriers

Brachytherapy Stranded Seeds

Brachytherapy Stranded Seeds

Configurations & Carriers

Seed Carrier (Eye Plaque)

Seed Carrier
(Eye Plaque)

Configurations & Carriers

Gold Fiducial Marker Needles

Gold Fiducial
Markers

Fiducial Markers

AnchorMarker - Fiducial Marker

AnchorMarker

Fiducial Markers

C20 Brachytherapy Seed Cartridges

Configurations & Carriers

C20™ Seed Cartridges

More
Preloaded Brachytherapy Needle Trays

Configurations & Carriers

Preloaded Needle Trays

More
Brachytherapy Stranded Seeds

Configurations & Carriers

Brachytherapy Stranded Seeds

More
ANCHORSEED Proprietary, synthetic bio-absorbable polymer seed encapsulation design

Configurations & Carriers

AnchorSeed® Encapsulated Seeds

More
Seed Carrier (Eye Plaque)

Configurations & Carriers

Eye Plaque Brachytherapy Seed Carriers

More

TheraSeed® - Palladium-103

Shorter half-life and lower energy photons provide distinct radiobiologic advantages over I-125, and may achieve greater disease control over I-125. 1
Implants demonstrate greater dose heterogeniety, which is associated with improved oncologic outcomes. 1

Interested in learning more?

Contact us today to learn more about TheraSeed® Pd-103 and how Theragenics Brachytherapy can support your practice and patient care.

TheraSeed® Pd-103 is indicated for the treatment of localized and unresectable tumors with low to moderate radiosensitivity. Tumors may be recurrent or residual following external beam radiation or excision of primary tumor.

  1. Tang, et. al., “Outcomes after PD-103 versus I-125 for low dose rate prostate brachytherapy monotherapy: an international, multi-institutional study”, Radiotherapy and Oncology, Volume 183, June 2023, 109599.
  2. Rivard, et al., “Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations”, Med Phys. 31, 663-674, (2004)

TheraSeed® Pd-103 source and accessories should be used by physicians who are qualified by training and experience in the safe use and handling of radionuclide brachytherapy sources and whose experience and training has been approved by the appropriate government authorities authorized to license the use of radioactive materials.

Information intended for the USA. Indications may vary in different countries; please either consult the appropriate IFU or your local distributor.

Related Products

AGX-100 - Iodine-125 Brachytherapy Seeds

AgX100®
Iodine-125 Seeds

Brachytherapy Seeds

Cesium-131
Seeds

Brachytherapy Seeds

About Us

We design and deliver innovative solutions that consistently improve patient outcomes.

;

Our History

Learn how we’re building on over 40 years of medical device excellence.

;

Careers

Ready to join a dynamic team committed to advancing medical device innovation?